Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 177, Issue 1-2, Pages 181-188Publisher
ELSEVIER
DOI: 10.1016/j.jneuroim.2006.04.023
Keywords
neurotoxicity; multiple sclerosis; therapeutics; neuroimmunology
Categories
Ask authors/readers for more resources
Beneficial effects of intravenous immunoglobulin (IVIg) in relapsing-remitting multiple sclerosis (MS) have been described, including a decrease of brain atrophy. We have previously shown that activated T cells kill neurons in culture. In this manuscript, we show that the pretreatment of activated T cells with IVIg attenuates T cell neurotoxicity. This is attributed to the ability of IVIg to decrease the adhesion of T cells onto neurons, possibly through an effect on LFA-1, and by lowering the levels of Fas and FasL on T cells. Our results are relevant to understanding how therapies affect the MS disease process. (c) 2006 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available